Код долголетия. 12 понятных и доступных способов сохранить здоровье, ясность ума и привлекательность на долгие годы - Джеймс ДиНиколантонио

22. Blagosklonny, M. V. “Calorie Restriction: Decelerating mTOR-Driven Aging from Cells to Organisms (Including Humans).” Cell Cycle 9, no. 4 (2010): 683–688.

23. Cuervo, A. M., et al. “Autophagy and Aging: The Importance of Maintaining ‘Clean’ Cells.” Autophagy 1, no. 3 (2005): 131–140.

24. Jia, K., and B. Levine. “Autophagy Is Required for Dietary Restriction-Mediated Life Span Extension in C. elegans.” Autophagy 3, no. 6 (2007): 597–599; Melendez, A., et al. “Autophagy Genes Are Essential for Dauer Development and Life-Span Extension in C. elegans.” Science 301, no. 5638 (2003): 1387–1391.

25. Alvers, A. L., et al. “Autophagy Is Required for Extension of Yeast Chronological Life Span by Rapamycin.” Autophagy 5, no. 6 (2009): 847–849.

26. Hardie, D. G., F. A. Ross, and S. A. Hawley. “AMPK: A Nutrient and Energy Sensor That Maintains Energy Homeostasis.” Nature Reviews Molecular Cell Biology 13, no. 4 (2012): 251–262.

27. Canto, C., and J. Auwerx. “Calorie Restriction: Is AMPK a Key Sensor and Effector?” Physiology (Bethesda) 26, no. 4 (2011): 214–224.

28. Lyons, C., and H. Roche. “Nutritional Modulation of AMPK-Impact upon Metabolic-Inflammation.” International Journal of Molecular Sciences 19, no. 10 (2018): 3092.

29. Anson, R. M., B. Jones, and R. de Cabod. “The Diet Restriction Paradigm: A Brief Review of the Effects of Every-Other-Day Feeding.” Age (Dordr) 27, no. 1 (2005): 17–25.

30. Hambly, C., et al. “Repletion of TNF-alpha or Leptin in Calorically Restricted Mice Suppresses Post-Restriction Hyperphagia.” Disease Model Mechanisms 5, no. 1 (2012): 83–94.

31. Goodrick, C. L., et al. “Effects of Intermittent Feeding upon Growth and Life Span in Rats.” Gerontology 28, no. 4 (1982): 233–241.

32. Goldberg, E. L., et al. “Lifespan-Extending Caloric Restriction or mTOR Inhibition Impair Adaptive Immunity of Old Mice by Distinct Mechanisms.” Aging Cell 14, no. 1 (2015): 130–138.

33. Ingram, D. K., et al. “Calorie Restriction Mimetics: An Emerging Research Field.” Aging Cell 5, no. 2 (2006): 97–108.

1. “Did a Canadian Medical Expedition Lead to the Discovery of an Anti-Aging Pill?” Bloomberg News, February 12, 2015. Открыто по адресу https://business.financialpost.com/news/did-a-canadian-medical-expedition-lead-to-the-discovery-of-an-anti-aging-pill.

2. Mohsin, N., et al. “Complete Regression of Visceral Kaposi’s Sarcoma After Conversion to Sirolimus.” Experimental and Clinical Transplantation 3, no. 2 (2005): 366–369.

3. Blagosklonny, M. V. “Aging and Immortality: Quasi-Programmed Senescence and Its Pharmacologic Inhibition.” Cell Cycle 5, no. 18 (2006): 2087–2102.

4. Ortman, J., V. Velkoff, and H. Hogan. “An Aging Nation: The Older Population in the United States.” May 2014. Открыто по адресу www.census.gov/prod/2014pubs/p25-1140.pdf.

5. Christensen, K., et al. “Ageing Populations: The Challenges Ahead.” The Lancet 374, no. 9696 (2009): 1196–1208; Drachman, D. A. “Aging of the Brain, Entropy, and Alzheimer Disease.” Neurology 67, no. 8 (2006): 1340–1352; Holroyd, C., C. Cooper, and E. Dennison. “Epidemiology of Osteoporosis.” Best Practice & Research: Clinical Endocrinology & Metabolism 22, no. 5 (2008): 671–685.

6. Nair, S., and J. Ren. “Autophagy and Cardiovascular Aging: Lesson Learned from Rapamycin.” Cell Cycle 11, no. 11 (2012): 2092–2099.

7. Powers, R. W., 3rd, et al. “Extension of Chronological Life Span in Yeast by Decreased TOR Pathway Signaling.” Genes & Development 20, no. 2 (2006): 174–184.

8. Robida-Stubbs, S., et al. “TOR Signaling and Rapamycin Influence Longevity by Regulating SKN-1/Nrf and DAF-16/FoxO.” Cell Metabolism 15, no. 5 (2012): 713–724.

9. Bjedov, I., et al. “Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila Melanogaster.” Cell Metabolism 11, no. 1 (2010): 35–46.

10. Harrison, D., et al. “Rapamycin Fed Late in Life Extends Lifespan in Genetically Heterogeneous Mice.” Nature 460 (2009): 392–395.

11. Halford, B. “Rapamycin’s Secrets Unearthed.” Chemical & Engineering News 94, no. 29 (2016): 26–30.

12. Urfer, S. R., et al. “A Randomized Controlled Trial to Establish Effects of Short-Term Rapamycin Treatment in 24 Middle-Aged Companion Dogs.” Geroscience 39, no. 2 (2017): 117–127.

13. Lelegren, M., et al. “Pharmaceutical Inhibition of mTOR in the Common Marmoset: Effect of Rapamycin on Regulators of Proteostasis in a Non-Human Primate.” Pathobiology of Aging & Age Related Diseases 6 (2016): 31793.

14. Spilman, P., et al. “Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-Beta Levels in a Mouse Model of Alzheimer’s Disease.” PLoS One 5, no. 4 (2010): e9979.

15. Majumder, S., et al. “Lifelong Rapamycin Administration Ameliorates Age-Dependent Cognitive Deficits by Reducing IL-1beta and Enhancing NMDA Signaling.” Aging Cell 11, no. 2 (2012): 326–335.

16. Liu, Y., et al. “Rapamycin-Induced Metabolic Defects Are Reversible in Both Lean and Obese Mice.” Aging (Albany NY) 6, no. 9 (2014): 742–754.

17. Kolosova, N. G., et al. “Prevention of Age-Related Macular Degeneration-Like Retinopathy by Rapamycin in Rats.” American Journal of Pathology 181, no. 2 (2012): 472–477.

18. Halloran, J., et al. “Chronic Inhibition of Mammalian Target of Rapamycin by Rapamycin Modulates Cognitive and Non-Cognitive Components of Behavior Throughout Lifespan in Mice.” Neuroscience 223 (2012): 102–113; Tsai, P. T., et al. “Autistic-Like Behaviour and Cerebellar Dysfunction in Purkinje Cell Tsc1 Mutant Mice.” Nature 488, no. 7413 (2012): 647–651; Perl, A. “mTOR Activation is a Biomarker and a Central Pathway to Autoimmune Disorders, Cancer, Obesity, and Aging.” Annals of the New York Academy of Science 1346, no. 1 (2015): 33–44.

19. Mahe, E., et al. “Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy.” Transplantation 79, no. 4 (2005): 476–482; McCormack, F. X., et al. “Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis.” New England Journal of Medicine 364, no. 17 (2011): 1595–1606.

20. Mendelsohn, A. R., and J. W. Larrick. “Dissecting Mammalian Target of Rapamycin to Promote Longevity.” Rejuvenation Research 15, no. 3 (2012): 334–337.

21. Johnston, O., et al. “Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients.” Journal of the American Society of Nephrology 19, no. 7 (2008): 1411–1418.

22. Lamming, D. W. “Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and Beyond.” Cold Spring Harbor Perspectives in Medicine 6, no. 5 (2016).

23. См. примечание 20 выше.

24. Arriola Apelo, S. I., et al. “Alternative Rapamycin Treatment Regimens Mitigate the Impact of Rapamycin on Glucose Homeostasis and the Immune System.” Aging Cell 15, no. 1 (2016): 28–38.

25. См. примечание 11 выше.